Format

Send to

Choose Destination
Infect Dis Clin North Am. 2019 Dec;33(4):891-905. doi: 10.1016/j.idc.2019.08.001.

The Middle East Respiratory Syndrome (MERS).

Author information

1
Special Infectious Agents Unit, King Fahd Medical Research Centre, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.
2
Department of Medicine and Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
3
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Infectious Diseases Division, Department of Medicine and Research, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia.
4
Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.
5
Center for Clinical Microbiology, University College London, Royal Free Campus 2nd Floor, Rowland Hill Street, London NW3 2PF, United Kingdom.

Abstract

The Middle East respiratory syndrome (MERS) is a novel lethal zoonotic disease of humans caused by the MERS coronavirus (MERS-CoV). Although MERS is endemic to the Middle East, travelers have exported MERS-CoV on return to their home countries. Clinical manifestations range from mild to severe acute respiratory disease and death. The elderly, immunocompromised, and those with chronic comorbid liver, lung, and hepatic conditions have a high mortality rate. There is no specific treatment. Person-to-person spread causes hospital and household outbreaks, and thus improved compliance with internationally recommended infection control protocols and rapid implementation of infection control measures are required.

KEYWORDS:

Epidemiology diagnosis; MERS-CoV; Middle East respiratory syndrome coronavirus; Treatment

PMID:
31668197
DOI:
10.1016/j.idc.2019.08.001
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center